TICKERNERD
Menu
INSPINSPHealthcare · Medical Devices

INSP Stock Forecast: Inspire Medical Systems, Inc. Price Predictions for 2026-2027

Last close, 4 Nov 2026
$67
+7.56% on the day

The 18 Wall Street analysts covering Inspire Medical Systems, Inc. hold a median 12-month price target of $70 — +4.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 88 of 100 as at 4 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$1.9B
Ticker Nerd rank
88/ 100
Median analyst target
$70
Analysts covering
18
Revenue$200.6M−7.6% y/y
Operating income−$514K
Net income$314K
Free cash flow$14.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−6.2%
1M
−4.8%
YTD
−27.8%
1Y
−21.7%
From 52W high
−53.8%
From 52W low
+66.2%
$40
$144
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

INSP stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Inspire Medical Systems, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 4 Nov 2026
88/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
98
Value
94
Revisions
89
Issuance
84
Volatility
68
Growth
58
Momentum
41
Size
36
Accruals
29

Quality (98): The business earns solid, repeatable profits on what it owns.

Accruals (29): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

INSP stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on INSP, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$40$60$80$100$120$140Jan 26Apr 26Jul 26Oct 26INSPHigh $97Median $70Low $40

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says18 analysts
4 Buy11 Hold3 Sell
Low $40Median $70High $97

The green dot is the last close — the median target sits +4.4% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 8 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
14 Oct 2026Truist SecuritiesMaintainsHold$62 → $78
7 Oct 2026BarclaysInitiatesUnderweight$65
2 Oct 2026Freedom Capital MarketsMaintainsBuy$97
2 Oct 2026Freedom Capital MarketsMaintainsBuy—
1 Oct 2026RBC CapitalMaintainsSector Perform$60 → $75
1 Oct 2026RBC CapitalMaintainsSector Perform—
21 Sept 2026Freedom Capital MarketsMaintainsBuy—
21 Sept 2026Freedom Capital MarketsMaintainsBuy$71 → $97
11 Sept 2026StifelMaintainsBuy$75 → $80
11 Sept 2026StifelMaintainsBuy—
4 Aug 2026BairdMaintainsNeutral$54 → $59
4 Aug 2026BairdMaintainsNeutral—
4 Aug 2026Evercore ISI GroupMaintainsIn-Line$40 → $54
4 Aug 2026Evercore ISI GroupMaintainsIn-Line—
4 Aug 2026JP MorganMaintainsNeutral—
4 Aug 2026JP MorganMaintainsNeutral$54 → $60
4 Aug 2026MizuhoMaintainsOutperform—
4 Aug 2026MizuhoMaintainsOutperform$55 → $65
4 Aug 2026OppenheimerUpgradeOutperform—
4 Aug 2026OppenheimerUpgradeOutperform$85

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

INSP appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

INSP vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 4 Nov 2026, Inspire Medical Systems, Inc. returned −21.7% against +14.8% for the S&P 500, dividends included.

INSP vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120140160180Jan 26Apr 26Jul 26Oct 26INSPS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

INSP analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
+39.5%
Analysts raising
2
Analysts cutting
0
Fundamentals

Inspire Medical Systems, Inc. (INSP) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
13.6×

Cheaper than 49% of US stocks

Price / sales
2.0×

Cheaper than 51% of US stocks

Price / book
2.3×

Cheaper than 39% of US stocks

EV / EBITDA
23.2×

Cheaper than 12% of US stocks

Growth & margins
Revenue growth (YoY)
−7.6%

Higher than 18% of US stocks

Earnings growth (YoY)
—
Gross margin
85.5%

Higher than 94% of US stocks

Operating margin
−0.3%

Higher than 31% of US stocks

Net margin
15.0%

Higher than 77% of US stocks

Returns & dividend
Return on equity
18.0%

Higher than 79% of US stocks

Return on assets
3.9%

Higher than 71% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Inspire Medical Systems, Inc. (INSP) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Inspire Medical Systems, Inc. has a market value of $1.9B and an enterprise value of $1.7B.

  • Revenue in the twelve months to 30 June 2026: $898.7M. The latest quarter shrank 7.6% year on year.

  • Net income over the same four quarters: $135.0M, a 15.0% net margin.

  • Diluted earnings per share, trailing twelve months: $4.62.

  • Free cash flow in the twelve months to 30 June 2026: $117.1M, after $40.0M of capital spending.

  • Inspire Medical Systems, Inc. spent $100.0M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 28.9M.

  • Trailing P/E: 13.6×; forward P/E: 40.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Inspire Medical Systems, Inc. employs 1,333 people — $674K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 3 Nov 2026

Data provided by Twelve Data

Peers

INSP vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
INSPInspire Medical Systems, Inc.$1.9B88
ALMRAlamar Biosciences, Inc. (California)$1.9B2
ESTAEstablishment Labs Holdings, Inc.$1.9B74
BFLYButterfly Network, Inc.$1.8B89
NVCRNovoCure Ltd.$1.7B97
CNMDCONMED Corp.$1.7B92
TMDXTransMedics Group, Inc.$2.5B40

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Inspire Medical Systems, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest INSP news & analysis

Inspire Medical Systems: The Moat Just Passed Its Worst-Case Stress Test

Seeking Alpha · 4 Nov 2026positive

The article says Inspire Medical Systems remained financially strong amid coding and reimbursement disruptions, with gross margin at 86% and nine-month operating cash flow of $82.5 million despite revenue declining 7.9% year over year. Management attributed nearly all of the shortfall to coding issues and expects growth to resume after a permanent CPT code takes effect in January 2028.

Why it matters — INSP watchers may consider how administrative headwinds and the expected timing of a permanent CPT code relate to the company’s recent revenue decline and outlook.

Inspire Medical Systems, Inc. to Present at the Stifel 2026 Healthcare Conference

GlobeNewsWire · 3 Nov 2026neutral

Inspire Medical Systems announced that its management team will present at the Stifel 2026 Healthcare Conference on November 10, 2026, at 2:40 p.m.

Why it matters — INSP watchers may note the scheduled conference presentation as an opportunity for the company’s management to address investors and other attendees.

These Analysts Increase Their Forecasts On Inspire Medical After Strong Q3 Results

Benzinga · 3 Nov 2026positive

Benzinga reports that Inspire Medical Systems announced upbeat third-quarter earnings on Monday. The headline says analysts increased their forecasts following the results.

Why it matters — INSP watchers may note the reported positive earnings and the headline’s mention of higher analyst forecasts.

Inspire Medical Systems, Inc. (INSP) Q3 2026 Earnings Call Transcript

Seeking Alpha · 3 Nov 2026neutral

The excerpt identifies Inspire Medical Systems’ Q3 2026 earnings call, held November 2, 2026, and lists company executives and participating analysts. It contains no earnings results or substantive discussion.

Why it matters — The excerpt confirms the call and its participants, but provides no business or financial details for INSP watchers to assess.

Inspire Medical Systems Q3 Earnings Call Highlights

MarketBeat · 3 Nov 2026neutral

Inspire Medical Systems reported third-quarter revenue of $206.7 million, down 7.9% year over year but up 3% sequentially. Stronger-than-expected U.S. performance offset weaker international results; management said coding and reimbursement challenges continued, while expressing growing confidence that the disruption is easing.

Why it matters — INSP watchers may note the contrasting regional performance and management’s view that reimbursement-related disruption could be easing.

FAQ

Frequently asked questions about INSP stock

What is the INSP stock price forecast for 2026-2027?

The 18 Wall Street analysts covering Inspire Medical Systems, Inc. have a median 12-month price target of $70, with estimates ranging from $40 to $97. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is INSP stock a buy right now?

Of the 18 analysts covering Inspire Medical Systems, Inc., 4 rate it a Buy, 11 a Hold and 3 a Sell. Ticker Nerd's systematic factor model ranks Inspire Medical Systems, Inc. 88 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank INSP?

As at 4 Nov 2026, Inspire Medical Systems, Inc. ranks 88 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (98 of 100).

Will INSP stock go up?

No one can know that. What the data says: the median 12-month target from 18 analysts implies +4.4% from the last close, and Ticker Nerd's factor model ranks Inspire Medical Systems, Inc. 88 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the INSP stock forecast for 2030?

No analyst covering Inspire Medical Systems, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for INSP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $40 to $97 over the next 12 months.

How has INSP stock performed over the past year?

Inspire Medical Systems, Inc. returned -21.7% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Inspire Medical Systems, Inc. do?

Inspire Medical Systems, Inc. is a medical technology company focused on minimally invasive solutions for obstructive sleep apnea.

What is the latest news on INSP?

The most recent item we track (Seeking Alpha, 4 Nov 2026): "Inspire Medical Systems: The Moat Just Passed Its Worst-Case Stress Test". The article says Inspire Medical Systems remained financially strong amid coding and reimbursement disruptions, with gross margin at 86% and nine-month operating cash flow of $82.5 million despite revenue declining 7.9% year over year. Management attributed nearly all of the shortfall to coding issues and expects growth to resume after a permanent CPT code takes effect in January 2028.

Company

About Inspire Medical Systems, Inc.

Inspire Medical Systems, Inc. is a medical technology company focused on minimally invasive solutions for obstructive sleep apnea. Its core product is the Inspire system, an implantable neurostimulation therapy that monitors breathing during sleep and delivers mild hypoglossal nerve stimulation to help maintain an open airway. The company serves patients with moderate to severe obstructive sleep apnea who are seeking an alternative to traditional mask-based treatments, and its offerings are used in hospitals, ambulatory surgery centers, sleep centers, and ENT care pathways. Inspire Medical Systems operates in the United States and selected international markets, with a business centered on device commercialization, physician education, and related patient support services. The company is headquartered in Golden Valley, Minnesota, and remains a specialized player in the sleep medicine and neuromodulation markets.

CEO Mr. Timothy P. Herbert · 1,333 employees · United States · https://www.inspiresleep.com